Top Markets
Coin of the day
Regnum Corp. Regnum Corp.

Regnum Corp.

RGMP
Rank in Stocks #42305
Regnum Corp. is dedicated to advancing and marketing therapeutic agents... Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV) from gaining entry into human cells. Headquartered in New York, New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$2.30K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regnum Corp. (RGMP)

Category

P/B ratio for Regnum Corp. (RGMP)
P/B ratio as of 2026 TTM: 0
According to Regnum Corp. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Regnum Corp. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR